XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Composition of Other Balance Sheet Items (Tables)
 6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of inventories
Inventories, Net
June 30,
2022		December 31,
2021
(unaudited)
Raw materials$7,463 $7,325 
Work in process36,860 45,711 
Finished goods40,537 32,923 
Total$84,860 $85,959 
Schedule of property and equipment
Property and Equipment, Net
June 30,
2022		December 31,
2021
(unaudited)
Lab equipment and furniture$12,212 $12,287 
Leasehold improvements14,023 14,369 
Software1,007 4,776 
Computer equipment1,282 1,944 
Construction-in-progress— 33 
28,524 33,409 
Less accumulated depreciation and amortization(12,207)(16,454)
Property and equipment, net$16,317 $16,955 
Schedule of accounts payable and accrued liabilities
Accounts Payable and Accrued Liabilities
June 30,
2022		December 31,
2021
(unaudited)
Accounts payable$35,518 $9,331 
Accrued professional fees34,256 26,728 
Accrued compensation14,535 28,068 
Accrued product costs13,352 18,460 
Accrued royalties (1)
12,020 13,821 
Accrued clinical trial costs (2)
8,653 9,125 
Operating lease liabilities, current portion (3)
7,040 6,477 
Other accrued expenses7,626 5,673 
Total$133,000 $117,683 
_______________________________
(1) Refer to Note 16, Commitments and Contingencies.
(2) Includes preclinical and all clinical trial-related costs.
(3) Refer to Note 13, Leases.
Schedule of accrued product returns and rebates
Accrued Product Returns and Rebates
June 30,
2022		December 31,
2021
(unaudited)
Accrued product rebates$108,648 $97,597 
Accrued product returns37,113 35,127 
Total$145,761 $132,724 
Other liabilities
Other Liabilities
June 30,
2022		December 31,
2021
 (unaudited)
Nonrecourse liability related to sale of future royalties, long-term$1,364 $5,977 
Other liabilities10,601 10,403 
Total$11,965 $16,380